Treatment
Dapagliflozin clinical trials
We’re tracking 85 recruiting studies that include Dapagliflozin, each written for real people, not researchers, below.
Recruiting studies
- NCT07083388RecruitingPhase 1
Study of how different forms of BR3006 work in healthy adults
This trial tests how the body processes different forms of a drug called BR3006 in healthy volunteers. It compares a single tablet (BR3006) to a combination of three separate components (BR3006A, BR3006B, and BR3006C) given together. This helps researchers understand if the combination works the same as the single tablet.
Seoul, Gwanak-guAges 19 years+ - NCT07083401RecruitingPhase 1
Study of a New Drug Combination in Healthy Adults
This trial tests how a new combination of drugs (BR3006A, BR3006B, and BR3006C) is absorbed and processed by the body when taken together, compared to a single tablet (BR3006). It is for healthy adults to understand the safety and behavior of the medication.
Seoul, Gwanak-guAges 19 years+ - NCT06668389RecruitingPhase 4
Testing a diabetes medicine for repaired tetralogy of Fallot
This study tests a type of diabetes medicine (SGLT2 inhibitor) to see if it can help people who had surgery for tetralogy of Fallot feel better and have stronger heart and lung function. It may be a good fit if you are an adult with repaired tetralogy of Fallot and do not have certain other health problems.
Hong KongAges 18 years+ - NCT06140537RecruitingPhase 4
Dapagliflozin for kidney and heart health after transplant
This study tests whether a diabetes drug called dapagliflozin (Farxiga) can help protect your kidney function and heart health after a kidney transplant. It's for people who have had a transplant for at least a year and have diabetes or post-transplant diabetes.
Aurora, ColoradoAges 18–80 - NCT06626737RecruitingPhase 2
Testing dapagliflozin to prevent GVHD after stem cell transplant
This trial tests whether adding dapagliflozin (a diabetes medication) to standard care can help prevent graft-versus-host disease after a stem cell transplant for blood cancer. It may be an option for adults who are about to receive a transplant from a half-matched or unrelated donor.
Suzhou, JiangsuAges 18–65 - NCT06845163RecruitingPhase 2
Testing dapagliflozin for diabetic macular edema
This study tests whether a medication called dapagliflozin, which is usually used for diabetes and heart failure, can help reduce swelling in the retina (diabetic macular edema) and improve vision. It is for people with type 2 diabetes who are already taking insulin and metformin.
Alexandria, Alexandria GovernorateAges 18–85 - NCT06887062RecruitingPhase 2
Testing dapagliflozin and bosentan for large vessel vasculitis
This trial tests two drugs, dapagliflozin and bosentan, to see if they help people with large vessel vasculitis who have been in remission for at least 6 months. The goal is to prevent flares and improve blood vessel health.
EdinburghAges 18 years+ - NCT06785116RecruitingPhase 4
Study on dapagliflozin for heart health after a hypertensive pregnancy
This trial tests a medicine called dapagliflozin (DAPA) to see if it reduces heart risk in women who had high blood pressure or preeclampsia during pregnancy. It is designed for those who had severe blood pressure rises around delivery or a high BNP level, a marker of heart strain.
Ann Arbor, MichiganAges 18 years+ - NCT06762964RecruitingPhase 2
Dapagliflozin for Failing Fontan Circulation
This study tests whether a medication called dapagliflozin (a pill for heart failure) can help people with a Fontan circulation who feel short of breath. It aims to improve symptoms and quality of life.
Rochester, MinnesotaAges 18 years+ - NCT06642272RecruitingPhase 4
Comparing two diabetes drugs in real-world use
This trial compares two common diabetes medications, empagliflozin and dapagliflozin, to see which works better in everyday practice. It aims to find the best treatment option for patients with type 2 diabetes.
CopenhagenAges 18 years+ - NCT05762952RecruitingPhase 1
Dapagliflozin study for heart micro-blood-flow symptoms in women
This early-phase study tests whether dapagliflozin can improve tiny blood-vessel function in women who have heart-ache-like symptoms but no major blockage on heart scans. If it works, it may help symptoms related to “microvascular” heart circulation problems.
Charlottesville, VirginiaAges 18–99 - NCT06560801RecruitingPhase 4
Dapagliflozin for kidney health after transplant
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
Erlangen, BavariaAges 18–75 - NCT06427226RecruitingPhase 2
Testing dapagliflozin to protect the heart during breast cancer chemo
This trial tests whether a daily pill called dapagliflozin can help protect the heart from damage caused by doxorubicin chemotherapy in people being treated for early-stage breast cancer. If you are starting doxorubicin and have a healthy heart, this might lower your risk of heart problems later.
Alexandria, Bab SharqiAges 18–65 - NCT06420167RecruitingPhase 2
Dapagliflozin for kidney AL amyloidosis
This trial tests whether a diabetes medicine called dapagliflozin can help protect kidney function in people with AL amyloidosis. You must live in Michigan and have stable or improving protein in your urine.
Detroit, MichiganAges 18 years+ - NCT06174753RecruitingPhase 3
Dapagliflozin for large heart attacks (STEMI)
This trial tests whether a diabetes drug called dapagliflozin can help people recover from a major heart attack (STEMI). You may qualify if you had a large heart attack within the last 12 hours and have not had a heart attack before.
Ottawa, OntarioAges 18 years+ - NCT05989347RecruitingPhase 1
Dapagliflozin with chemo for breast cancer
This trial tests whether adding the drug dapagliflozin (a pill that lowers blood sugar) to standard chemotherapy before breast cancer surgery can improve outcomes. It is for women with high insulin levels and a higher BMI who are about to start chemotherapy.
New Haven, ConnecticutAges 18 years+ - NCT05764057RecruitingPhase 3
Dapagliflozin to help the heart heal after a heart attack
This trial tests whether dapagliflozin (a diabetes medicine also used for heart protection) can reduce harmful heart “remodeling” after an acute heart attack. It may help your heart function and structure recover over the following 6 months.
ParisAges 18 years+ - NCT05174052RecruitingPhase 3
Dapagliflozin for heart rhythm problems in diabetes
This trial studies dapagliflozin, a diabetes medicine, to see if it can help people with paroxysmal atrial fibrillation (irregular heart rhythm). If you have both diabetes and this type of AF, the study may offer a chance to improve your heart rhythm and outcomes.
Oklahoma City, OklahomaAges 18–85 - NCT07436663RecruitingPhase 4
Preventing heart damage from breast cancer chemotherapy with two diabetes drugs
This trial tests whether two different diabetes drugs (SGLT-2 inhibitors and DPP-4 inhibitors) can help prevent heart damage that anthracycline chemotherapy can cause in breast cancer patients. You would receive one of the two drugs during your treatment to see if it protects your heart.
Tanta, ElgharbeyaAges Any age - NCT06009874Recruiting
SGLT2 inhibitor early after heart attack to protect the heart
This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.
Shibīn al Kawm, MenofiaAges 18–80 - NCT07776054RecruitingPhase 4
SGLT2 inhibitor after heart shock for atrial fibrillation with heart failure
This study tests whether a diabetes drug called an SGLT2 inhibitor can help keep your heart in a normal rhythm after a procedure to shock it back into rhythm. It is for people with persistent atrial fibrillation and a type of heart failure where the heart is stiff.
Seoul, SeoulAges 19 years+ - NCT06642623RecruitingPhase 4
Study on heart and kidney health in type 2 diabetes
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
SeoulAges 19 years+ - NCT07662135RecruitingPhase 3
A study of elecoglipron for type 2 diabetes with kidney problems
This trial tests a new medicine called elecoglipron to see if it helps control blood sugar in people with type 2 diabetes who also have reduced kidney function. You would continue taking your current SGLT2i medication (like dapagliflozin).
Sun City, ArizonaAges 18 years+ - NCT07614230RecruitingPhase 4
SGLT2 drugs and heart artery health in diabetes
This study tests whether a diabetes medication called SGLT2 inhibitors can slow the buildup of plaque in heart arteries. Researchers will use special CT scans to track changes in your coronary arteries over time.
Beijing, Beijing MunicipalityAges 18–78
Common questions
- Are there clinical trials studying Dapagliflozin?
- Yes. Clin2 currently lists 85 recruiting studies that include Dapagliflozin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Dapagliflozin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Dapagliflozin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Dapagliflozin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.